1. Home
  2. CHRO vs GRNQ Comparison

CHRO vs GRNQ Comparison

Compare CHRO & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRO
  • GRNQ
  • Stock Information
  • Founded
  • CHRO 2002
  • GRNQ 2013
  • Country
  • CHRO United States
  • GRNQ Malaysia
  • Employees
  • CHRO N/A
  • GRNQ N/A
  • Industry
  • CHRO
  • GRNQ EDP Services
  • Sector
  • CHRO
  • GRNQ Technology
  • Exchange
  • CHRO Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • CHRO 8.1M
  • GRNQ 6.8M
  • IPO Year
  • CHRO 2024
  • GRNQ 2018
  • Fundamental
  • Price
  • CHRO $1.37
  • GRNQ $0.91
  • Analyst Decision
  • CHRO Strong Buy
  • GRNQ
  • Analyst Count
  • CHRO 1
  • GRNQ 0
  • Target Price
  • CHRO N/A
  • GRNQ N/A
  • AVG Volume (30 Days)
  • CHRO 2.1M
  • GRNQ 11.1K
  • Earning Date
  • CHRO 05-14-2025
  • GRNQ 04-09-2025
  • Dividend Yield
  • CHRO N/A
  • GRNQ N/A
  • EPS Growth
  • CHRO N/A
  • GRNQ N/A
  • EPS
  • CHRO N/A
  • GRNQ N/A
  • Revenue
  • CHRO N/A
  • GRNQ $3,496,405.00
  • Revenue This Year
  • CHRO N/A
  • GRNQ N/A
  • Revenue Next Year
  • CHRO N/A
  • GRNQ N/A
  • P/E Ratio
  • CHRO N/A
  • GRNQ N/A
  • Revenue Growth
  • CHRO N/A
  • GRNQ 0.54
  • 52 Week Low
  • CHRO $0.45
  • GRNQ $0.80
  • 52 Week High
  • CHRO $3.80
  • GRNQ $2.24
  • Technical
  • Relative Strength Index (RSI)
  • CHRO 46.67
  • GRNQ 48.55
  • Support Level
  • CHRO $1.29
  • GRNQ $0.87
  • Resistance Level
  • CHRO $1.65
  • GRNQ $0.95
  • Average True Range (ATR)
  • CHRO 0.20
  • GRNQ 0.04
  • MACD
  • CHRO 0.02
  • GRNQ 0.01
  • Stochastic Oscillator
  • CHRO 13.81
  • GRNQ 55.56

About CHRO Chromocell Therapeutics Corporation

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: